Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...
Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...
Eisai has highlighted Leqembi’s dual-action profile in the past as a potential edge over Eli Lilly’s rival Alzheimer’s med Kisunla, which only targets plaque and can be discontinued once a ...
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...
Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.
Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...
Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
Eisai reported strong Q3 2024 performance driven by its leading products, particularly LEQEMBI, which saw robust sales growth across key regions. Management expressed confidence in achieving its ...
Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the approval of Leqembi (lecanemab) for mild cognitive impairment due to ...